Eutilex.Co.Ltd
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headqua… Read more
Market Cap & Net Worth: Eutilex.Co.Ltd (263050)
Eutilex.Co.Ltd (KQ:263050) has a market capitalization of $24.12 Million (₩35.32 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #26305 globally and #1681 in its home market, demonstrating a 29.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eutilex.Co.Ltd's stock price ₩959.00 by its total outstanding shares 36830878 (36.83 Million).
Eutilex.Co.Ltd Market Cap History: 2018 to 2026
Eutilex.Co.Ltd's market capitalization history from 2018 to 2026. Data shows change from $666.21 Million to $24.12 Million (-35.31% CAGR).
Index Memberships
Eutilex.Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.01% | #894 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.01% | #894 of 1384 |
Weight: Eutilex.Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Eutilex.Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eutilex.Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Eutilex.Co.Ltd's market cap is 0.01 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $666.21 Million | $402.03 Million | -$13.23 Billion | 1.66x | N/A |
| 2019 | $515.35 Million | $408.88 Million | -$17.13 Billion | 1.26x | N/A |
| 2020 | $575.85 Million | $2.04 Billion | -$28.77 Billion | 0.28x | N/A |
| 2021 | $342.29 Million | $73.54 Million | -$29.89 Billion | 4.65x | N/A |
| 2022 | $167.02 Million | $215.66 Million | -$33.43 Billion | 0.77x | N/A |
| 2023 | $85.02 Million | $131.65 Million | -$27.72 Billion | 0.65x | N/A |
| 2024 | $48.40 Million | $9.53 Billion | -$29.17 Billion | 0.01x | N/A |
Competitor Companies of 263050 by Market Capitalization
Companies near Eutilex.Co.Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Eutilex.Co.Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Eutilex.Co.Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Eutilex.Co.Ltd's market cap moved from $666.21 Million to $ 24.12 Million, with a yearly change of -35.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩24.12 Million | -13.45% |
| 2025 | ₩27.87 Million | -42.41% |
| 2024 | ₩48.40 Million | -43.08% |
| 2023 | ₩85.02 Million | -49.10% |
| 2022 | ₩167.02 Million | -51.20% |
| 2021 | ₩342.29 Million | -40.56% |
| 2020 | ₩575.85 Million | +11.74% |
| 2019 | ₩515.35 Million | -22.64% |
| 2018 | ₩666.21 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Eutilex.Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.12 Million USD |
| MoneyControl | $24.12 Million USD |
| MarketWatch | $24.12 Million USD |
| marketcap.company | $24.12 Million USD |
| Reuters | $24.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.